Anti-tumour immunotherapy with Vγ9Vδ2 T lymphocytes: from the bench to the bedside.

Abstract : Gamma delta (γδ) Τ cells are non-conventional T lymphocyte effectors that can interact with and eradicate tumour cells. Several data demonstrate that these T cells, which are implicated in the first line of defence against pathogens, have anti-tumour activity against many cancers and suggest that γδ Τ cell-mediated immunotherapy is feasible and might induce objective tumour responses. Due to the importance of γδ Τ lymphocytes in the induction and control of immunity, a complete understanding of their biology is crucial for the development of a potent cancer immunotherapy. This review discusses recent advances in γδ Τ basic research and data from clinical trials on the use of γδ Τ cells in the treatment of different cancers. It analyses how this knowledge might be applied to develop new strategies for the clinical manipulation and the potentiation of γδ Τ lymphocyte activity in cancer immunotherapy.
Type de document :
Article dans une revue
British Journal of Haematology, Wiley, 2013, 160 (2), pp.123-32. 〈10.1111/bjh.12090〉
Liste complète des métadonnées

Littérature citée [93 références]  Voir  Masquer  Télécharger

http://www.hal.inserm.fr/inserm-00802672
Contributeur : Monique Frei <>
Soumis le : mercredi 20 mars 2013 - 11:39:41
Dernière modification le : vendredi 20 octobre 2017 - 01:17:36
Document(s) archivé(s) le : dimanche 2 avril 2017 - 15:38:15

Fichier

 Accès restreint
Fichier visible le : jamais

Connectez-vous pour demander l'accès au fichier

Identifiants

Collections

Citation

Mounia Braza, Bernard Klein. Anti-tumour immunotherapy with Vγ9Vδ2 T lymphocytes: from the bench to the bedside.. British Journal of Haematology, Wiley, 2013, 160 (2), pp.123-32. 〈10.1111/bjh.12090〉. 〈inserm-00802672〉

Partager

Métriques

Consultations de la notice

93